SUMMARY: Human plasma gelsolin was purified by column chromatography. The method yielded a protein of high purity and activity. Using this protein, we produced monoclonal antibody (Mab H6B11) against human plasma gelsolin by somatic cell fusion. This monoclonal antibody reacted in a dose-dependent manner with gelsolin derived from human plasma and platelets and neutralized depolymerizing activity to F-actin. It differed from the commercially available substance (Mab G4896; Sigma) in that the time required for the reaction between the antigen and antibody in the enzyme-linked immunosorbent assay could be shortened by one-third.
INTRODUCTION
Gelsolin, a regulatory protein of actin polymerization, was initially identified in macrophages (1) and subsequently in the platelets (2) and plasma (3) (4) (5) . Plasma gelsolin exhibits the same biochemical properties for actin as cytoplasmic gelsolin (6, 7) and is assumed to depolymerize and degrade the actin filaments in the circulation (8) . While the role of plasma gelsolin has been studied in some disorders to determine its clinical usefulness (9, 10) , it remains unknown. The plasma level of gelsolin in normal subjects is reported to be as high as that of prealbumin, being around 0.2 mg/ml (7) . Thus, plasma gelsolin clearly plays some physiological and pathophysiological roles in the blood. The lack of finding of the clinical significance of gelsolin likely reflects the instability of the assay method used, particularly the instability of antibody. We therefore tried to develop an anti-plasma-gelsolin antibody to investigate its role and to establish a practical test for use in the laboratory for studying plasma gelsolin.
MATERIALS AND METHODS
Reagents and equipments: Used in these experiments were DE53 (Whatman Bio Systems, Ltd., Maidstone, Kent, UK), Blue Sepharose CL-6B, PBE94, Polybuffer 74 (Pharmacia Fine Chemicals, Uppsala, Sweden), molecular weight standards (Bio-Rad Lab., Richmond, CA), Freund's complete adjuvant (Calbiochem-Behring Corp., La Jolla, CA), Freund's incomplete adjuvant (Difco Lab., Detroit, MI), fetal calf serum (HyClone Lab. Inc., Logan, UT), enzymelinked immunosorbent assay (ELISA) plates (Coster, Cambridge, MA), biotinylated anti-mouse antibodies for each class (Amersham International plc, Amersham, UK), avidin conjugated with alkaline phosphatase (Dakopatts als, Glostrup, Denmark), and Aminoplates for ELISA (Sumitomo Bakelite Co., Tokyo).
Purification of human plasma gelsolin: Fresh human plasma (1,200 ml), obtained from healthy donors was fractionated with 30-50% saturation of (NH4)2SO4. The sample was dialyzed against 10 mM Tris-HC1, pH 8.0 (buffer A), and loaded on a DE53 column equilibrated with buffer A. The column was washed with 0.05 M NaCl in buffer A, and eluted with a gradient of 0.05-0.25 M NaCI in buffer A. The fractions that depolymerized F-actin were detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and the fractions containing gelsolin were dialyzed against 50 mM Tris-HC1, pH 7.0 (buffer B). Column chromatography of the dialysate with Blue Sepharose CL-6B equilibrated in buffer B was carried out. The column was eluted with a gradient of 0-1.5 M KC1 in buffer B. The pooled active fractions were dialyzed against 0.025 M imidazole-HC1, pH 7.4 (buffer C) and loaded on a PBE94 column equilibrated in buffer C. The column was eluted with a gradient of pH 7.4-4.0 with 0.0094 M/pH unit Polybuffer 74, to yield pure gelsolin. All procedures were carried out at 4 C. Preparation of actin: Filamented actin (F-actin), which is the polymerized form of globular actin (G-actin), was purified from rabbit skeletal muscle by the method of Spudich and Watt (11) and used for experiments in 2 mM Tris-HC1(pH 8.0), 0.2 mM ATP, 0.5 mM 2-mercaptoethanol, 0.2 mM CaC12, 0.15 M KC1, and 2 mM MgC12 (buffer F) at 4 C.
Depolymerizing ability (viscosity-decrease activity) of gelsolin to F-actin: To detect the depolymerizing activity to F-actin by gelsolin, the sample solution (5 a1) and 195 ul of F-actin solution (32 pM) in buffer F were mixed and the mixture was drawn into a glass capillary tube. The tube was allowed to stand for 15 min at an angle of 15° from the horizontal. A small steel ball was placed into the top of the tube, and the time for it to move 7 cm from the starting position was measured (5, 12) . The falling time of buffer F (200 ,al, ti) was used as the zero control, and the time of 16 pM F-actin in buffer F (t2) was used as the positive control. The time for 200 pl of the mixture of 16 pM F-actin and various amounts of gelsolin in buffer F (tx) was measured to obtain the viscosity-decrease activity (VDAX) from the equation given in Fig. 1 (5) . When 200 pl of a mixture of 29 nM gelsolin and various amounts of F-actin in buffer F was drawn into a glass capillary tube and the time for the ball to fall (ty) was measured, the viscosity-decrease activity (VDAy) was obtained (Fig. 1) . Ten separate experiments were done under each condition; reproducibility had a CV of 3.0%.
Immunization o f mice and preparation o f monoclonal antibody: BALB/c mice (4-week old) were immunized intraperitoneally with human plasma gelsolin (0.01 mg/mouse) and Freund's complete adjuvant on day 1, and with 0.005 mg/mouse of plasma gelsolin and Freund's incomplete adjuvant on day 10. Immunization with Freund's incomplete adjuvant was repeated four times every 10 days. Following the final immunization, cell fusion was done between the splenocytes of the mice and the murine myeloma cells (P3-X63-Ag8.U1) by the method of Koehler and Mistein (13) . The fused cells were cultured in a medium of hypoxanthine-aminopterin thymidine and were screened visually for cell growth. The culture media were screened for anti-gelsolin antibody using the ELISA described below. Those populations of hybridoma cells identified as secreting anti-gelsolin antibody were cloned by limiting dilution. Each cloned hybridoma cell line was grown in tissue culture. IgG containing anti-gelsolin antibodies was purified by affinity chromatography on protein G-sepharose.
Enzyme-linked immunosorbent assay (ELISA): Hybridomas were selected as described below. All ELISAs were performed at 37 C unless otherwise specified. Human plasma gelsolin was coupled to an ELISA plate for 1 hr. After washing with phosphate buffered saline (PBS) containing 0.1% Tween 20 (PBS-T), residual protein-binding sites were blocked with 1% gelatin in PBS for 30 min. After washing with PBS-T, the sample solution was added to each well and incubated for 1 hr. After washing with PBS-T, biotinylated anti-mouse IgG antibody was added and incubated for 1 hr. After washing with PBS-T, avidin conjugated with alkaline phosphatase was added and incubated for 30 min. After washing with PBS-T, p-nitrophenyl phosphate disodium salt (2.5 mM) and MgC12 (0.5 mM) in diethanolamine buffer (10 mM; pH 9.5) were added. After the desired color intensity was achieved at room temperature, 3 N NaOH was added to stop the reaction and the absorbance was measured at 405 nm.
The immunoglobulin was typed by the procedures described with biotinylated anti-mouse antibodies for each class, subclass, and type (20) .
Gelsolin was quantified on the Aminoplate. Glutaraldehyde (2%) diluted in PBS was added to each well and incubated for 90 min. After washing with PBS, the sample solution (purified gelsolin or pooled human plasma) was diluted stepwise in PBS containing 0.01% bovine serum albumin, MgC12 (0.5 mM), and ethylene glycol bis (j3-aminoethyl ether) N,N'-tetraacetic acid (EGTA; 1 mM) and the diluted sample was added to each well. The subsequent steps were performed as described.
Interference of gelsolin-induced viscosity-decrease activity (VDA) with antigelsolin monoclonal antibody:
Ten microliters of 0.3 mg/ml of the purified monoclonal antibody in 0.9% NaCI and 10 pl of various concentrations of gelsolin obtained from plasma or platelet in buffer F were incubated at 37 C for 5 min and then mixed with 180 pl of F-actin in buffer F to obtain a final concentration of 16 pM F-actin. The mixture was drawn into a glass capillary tube and the time for the ball to fall was measured. Control experiments were done without antibody. The VDA was then calculated as described (5).
Other methods: Human platelet gelsolin was purified as described previously (14) . Protein concentrations were assayed by the method of Bradford (15) with bovine albumin as the standard. SDS-PAGE was done by the method of Laemmli (16) .
RESULTS

Purification of Human Plasma Gelsolin
Human plasma gelsolin was purified in three chromatographic steps on DE53, Blue Sepharose CL-6B, and PBE94. After the first DE53 chromatography, the pooled active fractions exhibited major and several minor bands on SDS-PAGE. With the two additional purification steps, a single band was obtained on SDS-PAGE.
The purified protein was at the position of 93,000 daltons, corresponding to the molecular weight of human plasma gelsolin (7). This protein was concentrated, dialyzed against PBS containing 50% glycerin, and stored at -20 C. The final yield was 2.1% by our method when human plasma was estimated to contain about 0.2 mg/ml gelsolin (7). Quantification was done with use of gelsolin purified from human plasma as described in Materials and Methods. The reaction time for gelsolin (antigen) and Mab H6B11 (anti-gelsolin antibody) was set at 10 min_ Fig. 6 . Quantification of gelsolin in pooled human plasma. Gelsolin in pooled human plasma was quantified as described in Materials and Methods. The reaction time between gelsolin (antigen) and Mab H6B11(anti-gelsolin antibody) was set at 17 minor 25 min. (17) (18) (19) . From these characteristics, this protein was regarded as human plasma gelsolin.
Preparation of Monoclonal Antibodies to Human Plasma Gelsolin
Five hybridoma cell lines that produced monoclonal antibodies against gelsolin were obtained by somatic cell fusion and cloning. One hybridoma cell line, H6B11, was amplified in tissue culture, and the monoclonal antibody H6B11 (Mab H6B11) was obtained from the culture media. It was identified by ELISA as the murine IgGl-ic subclass.
Effects o f Mab H6B11 on VDA o f Gelsolin
When we evaluated the antibody (Mab H6B11) for inhibition of the VDA of human plasma gelsolin to F-actin, a positive result was obtained (Fig. 3) . Since Mab H6B11 inhibits VDA, the line obtained from experiments with Mab H6B11 ( Fig. 3; open circles) is lower than the control (experiments without Mab H6B11; closed circles in Fig. 3 ).
Specificity o f Monoclonal Antibody H6B11
The specificity of Mab H6B11 and 911E2, the cell line obtained by further cloning from H6B11 (20) , was studied by ELISA. Human plasma gelsolin reacted in a dose-dependent manner with not only Mab H6B11 but also Mab 911E2 (Fig.  4) . However, the protein did not react with either Mab 278A9 (anti-ouabain antibody; 20) or Mab 623B4 (anti-carrot-p-galactosidase antibody). This finding shows that Mab H6B11 and 911E2 each react specifically with the molecule of human plasma gelsolin. Human platelet gelsolin was allowed to react with Mab H6B11 in ELISA with similar results. Mab H6B11 was judged to recognize a common epitope of both gelsolins.
Quantification o f Plasma Gelsolin with Use o f Mab H6B11 Whether Mab H6B11 would be useful in determining the plasma level of gelsolin was studied. Its measurement would be clinically important; in fact, it has been determined in only a few diseases (9,10). Purified human gelsolin was quantified with a simple equation by ELISA (Fig. 5) . The levels of gelsolin in pooled human plasma were also plotted partially on a straight line (Fig. 6) . These results allowed the calculation of plasma levels of gelsolin. 
Assessment of Reaction Time between Mab H6B11 and Gelsolin
The reaction time required for the desired absorbances in ELISA was compared between Mab H6B 11 and G4896 (Sigma), a commercially available monoclonal antibody against plasma gelsolin. Mab 116B11 reacted with gelsolin in 10 min to obtain the desired absorbance, while Mab G4896 required 30 min.
Thus, Mab H6B 11 reacted with gelsolin in one-third the time required for Mab G4896. (Fig. 7) .
DISCUSSION
Since gelsolin was first purified in 1979 (1), it has been purified from blood cells by various chromatographic techniques, including affinity chromatography on a ligand of either antibody against gelsolin (21) (22) (23) (24) or DNase I (25) (26) (27) , or by high performance liquid chromatography (HPLC; 28, 29) . These methods require numerous preparation steps and a variety of equipment. Gelsolin found in plasma exhibited a higher molecular weight than that in cytoplasm; its physiological role is unknown. Our objectives were to purify gelsolin from human plasma by a rapid convenient method, and to prepare monoclonal antibodies against this protein to allow further study on it.
In purifying gelsolin, we made several modifications in its separation.
Protein inhibitors are often added to the buffers used for chromatography since plasma contains many proteases. EGTA and ethylenediamine-tetraacetic acid (EDTA) are added in buffers to inhibit the activation of gelsolin by Ca+ + (30) (31) (32) (33) . Protease inhibitors such as trypsin inhibitor and leupeptin are also added in buffers to inhibit the degradation of gelsolin (2, 34, 35) . Of the several inhibitors studied to determine whether they could inhibit the degradation of gelsolin, only leupeptin has been found effective (36) . However, we did not use leupeptin in the buffers for chromatography in our work because of its high cost; thus, some degradation was observed in our study without leupeptin. A previous study on the purification of gelsolin showed the yield ratio of 8% (37) whereas we obtained a value of 2.1%. However, our rapid purification procedure recovered sufficient amounts of gelsolin of high activity.
The report by Channpoier et al. (21) is the only published study on the production of monoclonal antibody against human plasma gelsolin. This antibody was found to cross-react with platelet gelsolin on electroblotting. However, details (e.g., photographs of electroblotting, purification procedures, and titration techniques of antibody activity) were not clearly described. Researchers in that laboratory conducted immunoaffinity column chromatography using monoclonal antibody as a ligand (22) (23) (24) . Their monoclonal antibody is available as a reagent from Sigma Chemical Co. (St. Louis, MO; catalog #G4896). Since the information on the neutralization activity of this antibody and its effects on F-actin viscosity is not obtainable from the manufacturer, it is inconvenient for experimental use.
The monoclonal antibody, H6B 11 developed in the present study was characterized by ELISA and neutralization tests. Although it can be used for measuring plasma levels of gelsolin (Figs. 5 and 6), this should be accomplished by a sandwich method between Mab H6B 11 and anti-gelsolin polyclonal antibody (42) . The sandwich method requires a smaller volume of the sample than the method described in this paper, and would be particularly useful for assaying a large number of samples.
Additional work was done to compare the characteristics of the two monoclonal antibodies: H6B11 obtained in this study and G4896 (Sigma). Compared with G4896, the present antibody bound to gelsolin in a reaction time that was one-third that required by G4896 (Fig. 7) . This saved time in performing the ELISA and allowed us to establish an ELISA for measuring the plasma gelsolin level. Gelsolin exists in plasma in two forms, free and actingelsolin complex.
The free and actin-bound forms have been measured biochemically by rather complicated methods (38, 39) which are time-consuming, laborious, and thus, not suited for routine laboratory use.
ELISA is popular for routine laboratory use in measuring a variety of proteins because it enables their measurement in the order of nanomoles but without the use of radioisotopes. A decrease in plasma gelsolin has been reported in patients with acute lung injury as well as in those with malaria caused by Plasmodium falciparum (9,10) with a polyclonal antibody and a commercially available monoclonal antibody in an ELISA method. Plasma gelsolin is reported to be produced in skeletal muscles and in a hepatoma cell line, HepG2, but not in normal liver (40, 41) . Thus, plasma levels of gelsolin would be expected to be altered in various diseases. This antibody should be useful in establishing a new method for assaying gelsolin in plasma, and thus, in determining its physiological role.
